France
· Delayed Price · Currency is EUR NFL Biosciences Statistics
Total Valuation
NFL Biosciences has a market cap or net worth of EUR 16.79 million. The enterprise value is 14.72 million.
| Market Cap | 16.79M |
| Enterprise Value | 14.72M |
Important Dates
The last earnings date was Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NFL Biosciences has 9.83 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 9.83M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 22.68% |
| Owned by Institutions (%) | 0.25% |
| Float | 7.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 365,009.37 |
| PB Ratio | 17.20 |
| P/TBV Ratio | 20.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.07 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.35, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.35 |
| Quick Ratio | 2.23 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9,177.93 |
Financial Efficiency
Return on equity (ROE) is -313.76% and return on invested capital (ROIC) is -243.97%.
| Return on Equity (ROE) | -313.76% |
| Return on Assets (ROA) | -46.01% |
| Return on Invested Capital (ROIC) | -243.97% |
| Return on Capital Employed (ROCE) | -127.63% |
| Revenue Per Employee | 9 |
| Profits Per Employee | -416,168 |
| Employee Count | 5 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.17% in the last 52 weeks. The beta is 1.44, so NFL Biosciences's price volatility has been higher than the market average.
| Beta (5Y) | 1.44 |
| 52-Week Price Change | -7.17% |
| 50-Day Moving Average | 1.60 |
| 200-Day Moving Average | 1.90 |
| Relative Strength Index (RSI) | 60.04 |
| Average Volume (20 Days) | 32,163 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NFL Biosciences had revenue of EUR 46 and -2.08 million in losses. Loss per share was -0.21.
| Revenue | 46 |
| Gross Profit | -1.55M |
| Operating Income | -2.79M |
| Pretax Income | -2.72M |
| Net Income | -2.08M |
| EBITDA | -2.72M |
| EBIT | -2.79M |
| Loss Per Share | -0.21 |
Balance Sheet
The company has 2.11 million in cash and 40,975 in debt, giving a net cash position of 2.07 million or 0.21 per share.
| Cash & Cash Equivalents | 2.11M |
| Total Debt | 40,975 |
| Net Cash | 2.07M |
| Net Cash Per Share | 0.21 |
| Equity (Book Value) | 976,431 |
| Book Value Per Share | 0.10 |
| Working Capital | 1.92M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -6,065,415.22% |
| Pretax Margin | -5,904,889.13% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NFL Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -12.39% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NFL Biosciences has an Altman Z-Score of 1.77. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.77 |
| Piotroski F-Score | n/a |